EP3268493
Heilblóðbundið mRNA markefni til að segja fyrir um blöðruhálskirtilskrabbamein og aðferðir til að greina það
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
11.3.2016EP published:
5.1.2022EP application number:
16713202.6
EP translation filed:
15.2.2022Grant published:
15.3.2022EPO information:
European Patent Register
Max expiry date:
10.3.2036Expiry date:
10.3.2023
Title in English:
WHOLE BLOOD BASED MRNA MARKERS FOR PREDICTING PROSTATE CANCER AND METHODS OF DETECTING THE SAMELanguage of the patent:
English
Timeline
Today
11.3.2016EP application
5.1.2022EP Publication
15.2.2022Translation submitted
15.3.2022Registration published
10.3.2023Expires
Owner
Name:
Janssen Pharmaceutica NVAddress:
Turnhoutseweg 30, 2340 Beerse, BE
Inventor
Name:
RICCI, DeborahAddress:
Raritan, New Jersey 08869, US
Name:
GORMLEY, MichaelAddress:
Spring House, Pennsylvania 19477, US
Name:
THOMAS, ShibuAddress:
Spring House, Pennsylvania 19477, US
Name:
RAJPUROHIT, YashodaAddress:
Spring House, Pennsylvania 19477, US
Name:
SCHAFFER, MichaelAddress:
Spring House, Pennsylvania 19477, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201562132064 PDate:
12.3.2015Country:
US
Classification
Categories:
C12Q 1/6886
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 8.2.2022
Expires: 10.3.2023
Payer: Árnason Faktor ehf.